Background Few medical studies have clarified the prognostic factors that affect medical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy. International Prognostic Index (aa-IPI). Risk assessment according to SUVmax at relapse The median SUVmax was 10.9 (range, 2.9-33.0). The ideal cut-off for SUVmax was 6.0 according to ROC curve analysis. The area under the ROC curve of SUVmax was 0.811. The level of sensitivity and specificity were 90.1 and 73.1%, respectively. Depending on his or her SUVmax, each patient was classified into either the low (<6.0) or high SUVmax group (6.0). Relating to this cut-off value, significant variations in survival were observed (<0.001 for PFS and <0.001 for OS, Fig. 2A-B). Fig. 2 Assessment of medical outcomes according to a maximum standardized uptake value (SUVmax) cut-off of 6.0. Prognostic factors affecting medical outcomes To examine whether medical outcomes were affected by various prognostic factors (age65 years, low aa-IPI, SUVmax <6.0, time-to-relapse >12 weeks, and CR Telmisartan status after salvage therapy), the factors were analyzed regarding their prognostic significance for salvage therapy. In univariate analysis, a low aa-IPI (<0.001 for PFS, <0.001 for OS), SUVmax <6.0 (<0.001 for PFS, <0.001 for OS), time to relapse >12 months (=0.025 for PFS, <0.001 for OS), and CR status after the therapy (=0.002 for PFS, <0.001 for OS) were associated with both PFS and OS (Table 2). Table 2 Univariate analysis of the prognostic factors predicting the Telmisartan medical outcomes. Multivariate analysis revealed that a low aa-IPI (<0.001 for PFS, <0.001 for OS), SUVmax <6.0 (<0.001 for PFS, <0.001 for OS), and time to relapse 12 months (<0.057 for PFS, <0.001 for OS) were indie prognostic factors associated with favorable outcomes (Table 3). Table 3 Multivariate analysis of the prognostic factors predicting the medical outcomes. Conversation Few studies have been devoted to restorative options for individuals with relapsed DLBCL who are ineligible for HDT/ASCT. It is well known the prognosis is extremely poor with few restorative options. The best restorative treatment is definitely palliative chemotherapy together with additional interventions to preserve a high quality of existence. However, some subgroups of relapsed individuals with low risk accomplish a second good response and encounter long term survival. Therefore, it is important to identify prognostic factors for predicting long-term results in this populace. Several studies suggested the medical value of particular prognostic factors including a tumor mass Telmisartan dimensions larger than 10 cm, restorative regimens prior to ASCT, elevated LDH levels, short time to relapse, and an overall high disease burden [9,10,11,12,13,14]. However, the widely approved solitary prognostic model in the relapsed/refractory establishing could not become generalized. A recent study illustrated the prognostic significance of aa-IPI based on the medical data of individuals with relapsed NHL who underwent HDT/ASCT [15,16,17]. Guglielmi et al. also performed a retrospective analysis of aa-IPI factors for individuals with relapsed DLBCL and recognized relapse within 12 months of the initial analysis and aa-IPI factors as significant self-employed prognostic factors [18]. In addition, other medical studies shown the positive predictive value of aa-IPI [3,19,20]. However, Telmisartan these results cannot be generalized to all individuals with NHL because the aa-IPI factors were mostly focused on individuals who underwent HDT/ASCT. Conversely, Rabbit Polyclonal to EGFR (phospho-Ser1026) the present study was designed to evaluate the prognostic value of aa-IPI for individuals with relapsed or refractory DLBCL who were ineligible for HDT/ASCT, and the data suggested that a low aa-IPI is definitely associated with beneficial results for HDT/ASCT-ineligible individuals. Several research organizations have investigated the use of 18F-FDG PET/CT to predict the outcomes of.